Sungkyunkwan University (SKKU)

University / College


Location: Seoul, Korea, Republic of (KR) KR

ISNI: 000000012181989X

ROR: https://ror.org/04q78tk20

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY (2023) Balmaña J, Fasching P, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, et al. Journal article Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study (2022) Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Treatment of advanced heart failure in adults with congenital heart disease: a narrative review and clinical cases (2022) Sinning C, Huntgeburth M, Fukushima N, Tompkins R, Huh J, Tataneo S, Diller GP, et al. Journal article, Review article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis (2022) Balmana J, Fasching P, Delaloge S, Park YH, Eisen A, Bourgeois H, Kemp Z, et al. Conference contribution KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer (2022) Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors (2022) Zhou J, Zaiss M, Knutsson L, Sun PZ, Ahn SS, Aime S, Bachert P, et al. Journal article, Review article Limpet teeth microstructure unites auxeticity with extreme strength and high stiffness (2022) Oh SH, Kim JK, Liu Y, Wurmshuber M, Peng XL, Seo J, Jeong J, et al. Journal article, Original article Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. (2022) Meagher NS, Gorringe KL, Wakefield MJ, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, et al. Journal article